Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in <i> BRAF <sup>V600E</sup> </i> -Mutated Anaplastic Thyroid CarcinomaJennifer Wang, Maria E. Cabanillas, Mark Zafereo et al.|Thyroid|2019Cited by 229
Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF <sup>V600E</sup> -Mutated Anaplastic Thyroid CarcinomaSarah Hamidi, Maria E. Cabanillas, Priyanka Iyer et al.|Thyroid|2024Cited by 72
Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistanceSarah Hamidi, Ramona Dadu, Marie‐Claude Hofmann et al.|Frontiers in Endocrinology|2023Cited by 49
Initial Management of <i>BRAF </i>V600E-Variant Anaplastic Thyroid CancerSarah Hamidi, Maria E. Cabanillas, Ramona Dadu et al.|JAMA Oncology|2024Cited by 35
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancerVivek Subbiah, Jie Wu, Behrang Amini et al.|npj Precision Oncology|2024Cited by 24